Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032064587> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3032064587 endingPage "e15211" @default.
- W3032064587 startingPage "e15211" @default.
- W3032064587 abstract "e15211 Background: Immunotherapy approaches are limited in their ability to induce antigen-specific CD8+ T cells in vivo able to recognize and kill tumor cells. We developed a novel immunotherapy approach using enantiomerically pure, R-DOTAP cationic lipid nanoparticles and tumor-derived T cell antigens, and previously demonstrated that R-DOTAP formulations efficiently prime cytotoxic T cells through enhanced cross presentation and induction of type I interferons.[1] A phase I clinical trial of a R-DOTAP HPV16 peptide formulation confirmed induction of strong in vivo HPV-specific CD8+ cytolytic T-cells without associated systemic toxicities. In this study, we assessed R-DOTAP nanoparticle formulations containing whole protein (ovalbumin) or long multi-epitope peptides from the tumor antigen TARP (T-cell alternate reading frame protein): a 58-residue protein overexpressed in prostate and breast cancers, documented to be immunogenic in humans. Methods: R-DOTAP formulations were prepared containing ovalbumin (OVA) or TARP peptides. C57BL/6K mice were immunized with 10 μg/mouse of OVA plus R-DOTAP, CFA or sucrose on Days 0, 15 and 30. OVA-specific cellular and humoral responses following vaccination were assessed by measuring splenic CD4 and CD8 T cell IFN-γ production and circulating OVA-specific antibodies in serum. HLA-A2 transgenic mice (AAD mice) were vaccinated with long, multi-epitope TARP peptides delivered as an R-DOTAP admixture or with CFA or sucrose on Days 0 and 7. Antigen-specific T cell responses were measured by IFN-γ ELISpot assay. Results: OVA R-DOTAP formulations induced strong antigen-specific effector CD4 and CD8 immune and memory responses detected 7 and 30 days, respectively, following vaccination as well as OVA-specific antibody responses. In TARP peptide vaccinated mice, R-DOTAP formulations were able to present multiple CD8 T cell epitopes and stimulate responses that were superior to CFA. Conclusions: Our results suggest that R-DOTAP is a versatile immune activating therapy that can be formulated with long, multi-epitope tumor-derived peptides or whole proteins. R-DOTAP formulations induce quantitatively robust antigen-specific CD4 and CD8 T cells in vivo compared to well-established immune stimulants. Reference: 1.Gandhapudi SK, Ward M, Bush JP et al. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J Immunol 2019;202:3524-3536" @default.
- W3032064587 created "2020-06-05" @default.
- W3032064587 creator A5008025285 @default.
- W3032064587 creator A5015324025 @default.
- W3032064587 creator A5035283039 @default.
- W3032064587 creator A5040458158 @default.
- W3032064587 creator A5079595702 @default.
- W3032064587 creator A5081812286 @default.
- W3032064587 date "2020-05-20" @default.
- W3032064587 modified "2023-09-24" @default.
- W3032064587 title "R-DOTAP (Versamune): A novel enantiospecific cationic lipid nanoparticle that induces CD4 and CD8 cellular immune responses to whole protein and tumor-specific peptide antigens." @default.
- W3032064587 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e15211" @default.
- W3032064587 hasPublicationYear "2020" @default.
- W3032064587 type Work @default.
- W3032064587 sameAs 3032064587 @default.
- W3032064587 citedByCount "2" @default.
- W3032064587 countsByYear W30320645872021 @default.
- W3032064587 countsByYear W30320645872023 @default.
- W3032064587 crossrefType "journal-article" @default.
- W3032064587 hasAuthorship W3032064587A5008025285 @default.
- W3032064587 hasAuthorship W3032064587A5015324025 @default.
- W3032064587 hasAuthorship W3032064587A5035283039 @default.
- W3032064587 hasAuthorship W3032064587A5040458158 @default.
- W3032064587 hasAuthorship W3032064587A5079595702 @default.
- W3032064587 hasAuthorship W3032064587A5081812286 @default.
- W3032064587 hasConcept C147483822 @default.
- W3032064587 hasConcept C153911025 @default.
- W3032064587 hasConcept C154317977 @default.
- W3032064587 hasConcept C167672396 @default.
- W3032064587 hasConcept C195616568 @default.
- W3032064587 hasConcept C202751555 @default.
- W3032064587 hasConcept C203014093 @default.
- W3032064587 hasConcept C2776090121 @default.
- W3032064587 hasConcept C2776946954 @default.
- W3032064587 hasConcept C2779053233 @default.
- W3032064587 hasConcept C55493867 @default.
- W3032064587 hasConcept C71924100 @default.
- W3032064587 hasConcept C86803240 @default.
- W3032064587 hasConcept C8891405 @default.
- W3032064587 hasConceptScore W3032064587C147483822 @default.
- W3032064587 hasConceptScore W3032064587C153911025 @default.
- W3032064587 hasConceptScore W3032064587C154317977 @default.
- W3032064587 hasConceptScore W3032064587C167672396 @default.
- W3032064587 hasConceptScore W3032064587C195616568 @default.
- W3032064587 hasConceptScore W3032064587C202751555 @default.
- W3032064587 hasConceptScore W3032064587C203014093 @default.
- W3032064587 hasConceptScore W3032064587C2776090121 @default.
- W3032064587 hasConceptScore W3032064587C2776946954 @default.
- W3032064587 hasConceptScore W3032064587C2779053233 @default.
- W3032064587 hasConceptScore W3032064587C55493867 @default.
- W3032064587 hasConceptScore W3032064587C71924100 @default.
- W3032064587 hasConceptScore W3032064587C86803240 @default.
- W3032064587 hasConceptScore W3032064587C8891405 @default.
- W3032064587 hasIssue "15_suppl" @default.
- W3032064587 hasLocation W30320645871 @default.
- W3032064587 hasOpenAccess W3032064587 @default.
- W3032064587 hasPrimaryLocation W30320645871 @default.
- W3032064587 hasRelatedWork W1967647128 @default.
- W3032064587 hasRelatedWork W2068000460 @default.
- W3032064587 hasRelatedWork W2083087192 @default.
- W3032064587 hasRelatedWork W2151897007 @default.
- W3032064587 hasRelatedWork W2155999541 @default.
- W3032064587 hasRelatedWork W2159337363 @default.
- W3032064587 hasRelatedWork W2801946978 @default.
- W3032064587 hasRelatedWork W3213677581 @default.
- W3032064587 hasRelatedWork W4220901781 @default.
- W3032064587 hasRelatedWork W4254282151 @default.
- W3032064587 hasVolume "38" @default.
- W3032064587 isParatext "false" @default.
- W3032064587 isRetracted "false" @default.
- W3032064587 magId "3032064587" @default.
- W3032064587 workType "article" @default.